Physician profile
Kimberly Hightower
NPI 1144220559
$799.28
in general payments reported to CMS, 2019-2025
12 companies · $128 in 2025
The $128 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $36.46 · 2021: $72.33 · 2022: $39.69 · 2023: $137 · 2024: $57.43 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $322.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $188.77 | 2019 | |
| Glaxosmithkline, LLC. | $179.25 | 2019-2023 | Bexsero, Pediarix, Rotarix |
| Pfizer INC. | $125.46 | 2019-2025 | |
| Seqirus USA INC | $77.71 | 2021-2025 | Flucelvax, Fluad |
| Phadia US INC. | $52.89 | 2019-2025 | Immunocap |
| Merck Sharp & Dohme LLC | $38.96 | 2020-2021 | |
| Novo Nordisk INC | $35.18 | 2025 | Wegovy |
| Sanofi Pasteur INC. | $33.15 | 2023-2024 | |
| Ultragenyx Pharmaceutical INC. | $20.27 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $18.81 | 2023 | Flumist Quadrivalent |
| Corium, LLC | $14.51 | 2023 | Azstarys |
| Biomarin Pharmaceutical INC. | $14.32 | 2025 | Voxzogo 1.2mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Hightower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.